Company Encyclopedia
View More
name
CISEN
603367.SH
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products in China and internationally. The company’s chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, narcotic analgesics, obstetrics and gynecology medication, digestive system medication, respiratory system medication, immune system drugs, and hormonal drugs. It also offers Chinese medicine preparations; complete and incomplete nutritional formula food; specific nutritionally complete formula foods; nutritious food; health food; API; and packaging products. The company was formerly known as Shandong Lukang Cisen Pharmaceutical Co., Ltd.
3.159 T
603367.SHMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking115/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.22%B
    • Profit Margin13.83%B
    • Gross Margin59.19%B
  • Growth ScoreD
    • Revenue YoY-16.26%E
    • Net Profit YoY-6.85%C
    • Total Assets YoY1.93%C
    • Net Assets YoY5.51%B
  • Cash ScoreD
    • Cash Flow Margin723.03%B
    • OCF YoY-16.26%E
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreA
    • Gearing Ratio18.72%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CISEN released its performance for the first three quarters, with a net profit attributable to the parent company of 382 million yuan, a year-on-year decrease of 4.05%

    According to the Zhitong Finance APP, CISEN disclosed its third-quarter report for 2025. The company achieved revenue of 2.584 billion yuan in the first three quarters, a year-on-year decrease of 13.94%; the net profit attributable to the parent company was 382 million yuan, a year-on-year decrease of 4.05%; the net profit excluding non-recurring gains and losses was 274 million yuan, a year-on-year decrease of 24.60%; the basic earnings per share were 0.84 yuan

    Zhitong·
    SH
    603367
    +0.83%
    Zhitong·
    SH
    603367
    +0.83%

    The influenza sector has risen again, with CISEN and TY PHAR. both hitting the daily limit

    The influenza sector has risen again, with CISEN and TY PHAR. both hitting the daily limit, while Harbin Three Alliance and Guangji Pharmaceutical previously locked their boards, and Hendi Pharmaceutical and Duoyi Pharmaceutical rose over 10%

    Zhitong·
    SH
    603367
    +0.83%
    SZ
    002728
    -1.66%
    Zhitong·
    SH
    603367
    +0.83%
    SZ
    002728
    -1.66%

    Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up

    Innovative drug concept stocks continue to be active, HUAPONT LIFE SCIENCES hits the limit up, Shen Lian Biomedical, Staidson BioPharm, CISEN, and WECOME follow suit

    Zhitong·
    SZ
    300683
    +0.99%
    SZ
    002004
    +0.83%
    SH
    688098
    +0.76%
    Zhitong·
    SZ
    300683
    +0.99%
    SZ
    002004
    +0.83%
    SH
    688098
    +0.76%

    CISEN: SSY GROUP completed the reduction of 4.52 million shares, with its shareholding decreasing to 5.11%

    CISEN announced that its shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd., which holds more than 5% of the shares, has completed its reduction plan, selling 4.52 million shares, reducing its shareholding ratio to 5.11%. Before the reduction, Shijiazhuang Four Pharmaceutical held 27.66 million unrestricted tradable shares, accounting for 6.11% of the total share capital. The reduction price range was between 19.70 - 21.17 yuan/share, with a total amount of 91.22564 million yuan

    Zhitong·
    SH
    603367
    +0.83%
    HK
    02005
    0.00%
    Zhitong·
    SH
    603367
    +0.83%
    HK
    02005
    0.00%

    Institutions sold 18 stocks including SourceCode Technology today, and bought CISEN for 116 million yuan

    On September 3rd, institutions net bought CISEN for 116 million yuan, XiaoCheng Technology for 111 million yuan, and Airo Energy for 72.55 million yuan, while net selling Yuanjie Technology for 409 million yuan, Chengdu Huamei for 112 million yuan, and Julun Intelligent for 98.88 million yuan. A total of 33 stocks had institutional trading

    36Kr·
    SH
    603367
    +0.83%
    36Kr·
    SH
    603367
    +0.83%
    © 2025 Longbridge｜Disclaimer